Developing a potential therepeutic for Alzheimer’s disease

Roberts group, in collaboration with the Mastren laboratory @MastrenLabUtah, graduate students, Dr. Aidan Bender (Nuclear Engineering, Mastren group) and Dr. Emily Kirkeby @_EmilyKirkeby_ (Chemistry, Roberts group) developed a ²¹³Bi-labeled pyridyl benzofuran for the targeted α-therapy of amyloid-β aggregates. The Roberts team @agr_chemistry worked together with Dr. Tara Mastren (Nuclear Engineering), Dr. Donna Cross (U of U Health, Radiology), and Dr. Satoshi Minoshima @drminoshima (U of U Health, Radiology).

 

 

“We are fortunate to work with this interdisciplinary team, where our small molecule design and synthesis efforts can be translated into potential radiolabeled therapeutics. Future efforts will develop alternative vector designs and radiolabeling strategies to improve the drug blood brain permeability and stability.” says Prof. Andrew G. Roberts.

 

Read the primary report here!

This work was highlighted at the U and at physicsworld, in addition to several other news outlets.

See more here!